← Aditya Birla Sun Life Mutual Fund

Aditya Birla Sun Life Nifty Healthcare ETF

Index/ETF Data as of Apr 2026 Comparing Mar 2026 → Apr 2026
Share: WhatsApp X
Stocks Held
20
Apr 2026
Equity Holdings
₹74.44 Cr
Equity only, excl. debt & cash
Top 5 Weight
50.5%
High concentration
Top 10 Weight
76.8%
High concentration
Changes
20
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
79.2% of portfolio
📋 What Happened This Month Among existing holdings, Fortis Healthcare Limited saw the biggest increase — now at 4.79% of the portfolio. Sun Pharmaceutical Industries Limited was trimmed the most, now at 19.05%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 79.2%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Feb 2026 Mar 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 78.1% 79.4% +1.3%
Healthcare Services 21.9% 20.6% -1.3%
Mar 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 79.4% 79.2% -0.3%
Healthcare Services 20.6% 20.8% +0.3%
Biggest Add
Fortis Healthcare Limited
+0.46% · now 4.79%
Biggest Trim
Sun Pharmaceutical Industries Limited
-0.40% · now 19.05%

What Changed?

Comparing Mar 2026 → Apr 2026

Mar 2026 Apr 2026
↑ 10 Increased ↓ 10 Decreased
#StockSectorMar 2026Apr 2026Change
1
Fortis Healthcare Limited
₹3.56 Cr
Healthcare Services 4.33% 4.79% +0.46%
2
Divi's Laboratories Limited
₹6.12 Cr
Pharmaceuticals & Biotechnology 7.90% 8.22% +0.32%
3
Glenmark Pharmaceuticals Limited
₹2.68 Cr
Pharmaceuticals & Biotechnology 3.35% 3.61% +0.26%
4
Laurus Labs Limited
₹3.17 Cr
Pharmaceuticals & Biotechnology 4.04% 4.26% +0.22%
5
Mankind Pharma Limited
₹1.88 Cr
Pharmaceuticals & Biotechnology 2.37% 2.53% +0.16%
6
Cipla Limited
₹5.46 Cr
Pharmaceuticals & Biotechnology 7.20% 7.33% +0.13%
7
Piramal Pharma Limited
₹74.30 L
Pharmaceuticals & Biotechnology 0.88% 1.00% +0.12%
8
Syngene International Limited
₹65.74 L
Healthcare Services 0.77% 0.88% +0.11%
9
Aurobindo Pharma Limited
₹2.88 Cr
Pharmaceuticals & Biotechnology 3.81% 3.86% +0.05%
10
Dr. Reddy's Laboratories Limited
₹5.97 Cr
Pharmaceuticals & Biotechnology 7.99% 8.02% +0.03%
#StockSectorMar 2026Apr 2026Change
1
Sun Pharmaceutical Industries Limited
₹14.18 Cr
Pharmaceuticals & Biotechnology 19.45% 19.05% -0.40%
2
Lupin Limited
₹4.14 Cr
Pharmaceuticals & Biotechnology 5.87% 5.56% -0.31%
3
Torrent Pharmaceuticals Limited
₹3.24 Cr
Pharmaceuticals & Biotechnology 4.61% 4.36% -0.25%
4
IPCA Laboratories Limited
₹1.58 Cr
Pharmaceuticals & Biotechnology 2.32% 2.12% -0.20%
5
Apollo Hospitals Enterprise Limited
₹5.82 Cr
Healthcare Services 7.98% 7.82% -0.16%
6
Biocon Limited
₹1.90 Cr
Pharmaceuticals & Biotechnology 2.69% 2.55% -0.14%
7
Max Healthcare Institute Limited
₹5.47 Cr
Healthcare Services 7.48% 7.35% -0.13%
8
Alkem Laboratories Limited
₹2.34 Cr
Pharmaceuticals & Biotechnology 3.24% 3.14% -0.10%
9
Abbott India Limited
₹97.92 L
Pharmaceuticals & Biotechnology 1.41% 1.32% -0.09%
10
Zydus Lifesciences Limited
₹1.65 Cr
Pharmaceuticals & Biotechnology 2.28% 2.22% -0.06%

Full Portfolio

20 stocks — Apr 2026

# Stock Sector Cap Weight & Value
1
₹14.18 Cr
Pharmaceuticals & Biotechnology
19.05%
2
₹6.12 Cr
Pharmaceuticals & Biotechnology
8.22%
3
₹5.97 Cr
Pharmaceuticals & Biotechnology
8.02%
4
₹5.82 Cr
Healthcare Services
7.82%
5
₹5.47 Cr
Healthcare Services
7.35%
6
₹5.46 Cr
Pharmaceuticals & Biotechnology
7.33%
7
₹4.14 Cr
Pharmaceuticals & Biotechnology
5.56%
8
₹3.56 Cr
Healthcare Services
4.79%
9
₹3.24 Cr
Pharmaceuticals & Biotechnology
4.36%
10
₹3.17 Cr
Pharmaceuticals & Biotechnology
4.26%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 Aditya Birla Sun Life Mutual Fund — Portfolio & Holdings
See all funds managed by Aditya Birla Sun Life Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.